32 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing to conduct
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
rigorous and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing
8-K
EX-99.1
xlvn jfyx4q24eobhj
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
5xypi94ab5u cv8
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
424B5
12gdhmdqzgae70 ra3
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
wui6poz2uunlufuc
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
xq35b3lekdnlql2vy2vx
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
0cx8dfb
23 Jun 20
Prospectus supplement for primary offering
4:06pm